Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice, very interesting. $IBIO$
Any reports from the PBVAB CONFRENCE ? $IBIO
http://finance.yahoo.com/news/easton-pharmaceuticals-bmv-medica-close-142340276.html
Easton Pharmaceuticals Inc. announces it has closed on the recently announced MOU with BMV Medica S.A. de C.V. to distribute injectable approved cancer drugs from Biolyse Pharma for Mexico and Latin America....
VDSI
6/3/2015 2:00 PM
VASCO Data Security International, Inc. (NASDAQ:VDSI) calls are flying off the shelves this afternoon -- tripling the expected intraday amount, and quadrupling the number of puts on the tape. Most active is the June 30 call, where it appears new positions are being purchased.
At last check, the tech stock was up 5.6% at $28.50. However, by purchasing the out-of-the-money calls, options traders think VDSI will charge even higher -- toppling the round-number $30 level by the close on Friday, June 19, when front-month options expire. The shares haven't explored territory that high since mid-February, when they soared to a seven-year peak of $31.84.
Technically speaking, VDSI's strong movement today has brought the stock into the black on a year-to-date basis. Year-over-year, however, the shares have been far more memorable, soaring 167% -- and benefiting from recent bounces off their 80- and 200-day trendlines.
It looks like short sellers are getting burned today. Over 46% of VASCO Data Security International, Inc.'s (NASDAQ:VDSI) float is dedicated to short interest. At the stock's average daily trading level, it would take over two weeks to repurchase all of these shorted shares.
Article by
Alex Eppstein
Ditto
nice volume
Way to go! Now lets do real legal research. Schedule 2.
The shorts own this one that's why. I'm out for now.
Look in the mirror :)
No squeeze yet, out at 28.03 for a heck of Gain. back in at
25. 66. Waiting for a another run.
after hrs $ 25.00 :)
News out from IBIO. Not sure how to copy and paste from phone.
I'm in the same frame of mind as Zacks analyst. A big surprise on revenue and earnings.The larger the short ratio the higher parabolic squeeze will be. :) VDSI $$$
Tuesday VSDI REPORTS $$$$$$$$$$$
Time is right for good SQUEEZE :)
VASCO to Showcase Innovative Authentication and Anti-Fraud Solutions at RSA Conference 2015
Source: PR Newswire (US)
SAN FRANCISCO, April 20, 2015 /PRNewswire/ -- VASCO Data Security International, Inc. (NASDAQ: VDSI), a global leader in authentication, digital signatures and identity management, will demonstrate innovative security solutions that protect assets, data, identities and transactions from the most sophisticated hacker attacks. VASCO will be in South Expo, Booth S1033 at RSA Conference 2015.
VASCO will showcase state-of-the-art authentication and anti-fraud solutions including:
DIGIPASS Mobile Application Securityprovides a suite of application security modules that deliver a new approach to application security. By integrating technology from Promon, VASCO is expanding its ability to protect the integrity of mobile applications, even in the presence of malware, to ensure that data and transactions are not compromised.IDENTIKEY Risk Manager is an upcoming, risk-based authentication solution featuring a real time risk engine that delivers multichannel user account takeover and financial transaction fraud detection and prevention.Cronto Visual Authentication and Transaction Signing delivers the highest level of transaction security with the greatest ease of use. Cronto technology utilizes a high definition color QR code to provide a unique authentication and visual transaction signing solution that is only available from VASCO.MYDIGIPASS Trusted Digital Identity Platform is VASCO's cloud-based, two-factor authentication and federated identity service that enables application providers to deliver a secure login experience using a single authenticated identity across multiple web and mobile applications.
RSA Conference 2015 is being held at Moscone Center in San Francisco, from April 20-24, 2015. VASCO is located in the South exhibit hall, booth S1033.
About VASCO:
VASCO is a world leader in providing two-factor authentication and digital signature solutions to financial institutions. More than half of the top 100 global banks rely on VASCO solutions to enhance security, protect mobile applications and meet regulatory requirements. VASCO also secures access to data and applications in the cloud, and provides tools for application developers to easily integrate security functions into their web-based and mobile applications. VASCO enables more than 10,000 customers in 100 countries to secure access, manage identities, verify transactions, and protect assets across financial, enterprise, E-commerce, government and healthcare markets. Learn more about VASCO at www.vasco.com and on Twitter, LinkedIn and Facebook.
For more information:
VASCO Corporate Communications
+1-847-370-1486 (US) or +32 2 609 97 00 (ROW)
pr@vasco.com
Trademarks
VASCO®, DIGIPASS® and the logo are registered or unregistered trademarks of VASCO Data Security, Inc. and/or VASCO Data Security International GmbH in the U.S. and other countries
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vasco-to-showcase-innovative-authentication-and-anti-fraud-solutions-at-rsa-conference-2015-300068335.html
SOURCE VASCO Data Security International, Inc.
?
Copyright 2015 PR Newswire
The short squeeze on VDSI IMO is going to be epic.
A federal judge on Friday explained in her written order why she decided not to overturn the federal government's classification of marijuana as a dangerous drug. In this June 25, 2014 file photo, a ladybug crawls on a marijuana plant at Sea of Green Farms, a recreational pot grower in Seattle. (AP Photo/Ted S. Warren, File)
Photo: Ted S. Warren / Ted S. Warren / Associated Press
A federal judge on Friday explained in her written order why she... Judge gives her reasons for deciding that pot is still dangerous 1 / 1
The federal judge who allowed Northern California pot growers to challenge the government's ban on marijuana says she decided to uphold the law in the end because, although nearly half the states allow for medical marijuana, there are "disagreements among well-informed experts" about whether the plant has any medicinal value.
That dispute among experts shows that Congress had an adequate "rational basis" for classifying marijuana among the most dangerous drugs, said U.S. District Judge Kimberly Mueller of Sacramento in a written ruling Friday, two days after she refused to dismiss pot cultivation charges against a dozen defendants.
Mueller had granted the defendants a hearing in October, to make their case that they were being prosecuted under an unconstitutional law. It was the first time in several decades that a federal judge had allowed defendants in a U.S. criminal case to challenge the constitutionality of the strict national prohibition on marijuana.
Although the defendants have not claimed they were growing marijuana for medical use, they argued that the charges were invalid because they were based on a law that treats pot more harshly than drugs with fewer benefits and more dangers...
Tip of the iceberg
Yahoo News
Illustration file picture shows a man typing on a computer keyboard in Warsaw
Israeli military networks breached by hackers: researchers
.
Reuters By Joseph Menn 10 hours ago
By Joseph Menn
2015 Mortgage Rates Take Huge Dip - 2.83% APR
LendingTree Sponsor
?
SAN FRANCISCO (Reuters) - Hackers have managed to penetrate computer networks associated with the Israeli military in an espionage campaign that skillfully packages existing attack software with trick emails, according to security researchers at Blue Coat Systems Inc.
The four-month-old effort, most likely by Arabic-speaking programmers, shows how the Middle East continues to be a hotbed for cyber espionage and how widely the ability to carry off such attacks has spread, the researchers said.
Waylon Grange, a researcher with the Blue Coat [PRJCBB.UL] who discovered the campaign, said the vast majority of the hackers' software was cobbled together from widely available tools, such as the remote-access Trojan called Poison Ivy.
The hackers were likely working on a budget and had no need to spend much on tailored code, Grange said, adding that most of their work appeared to have gone into so-called social engineering, or human trickery.
The hackers sent emails to various military addresses that purported to show breaking military news, or, in some cases, a clip featuring "Girls of the Israel Defense Forces." Some of the emails included attachments that established "back doors" for future access by the hackers and modules that could download and run additional programs, according to Blue Coat.
Using standard obfuscation techniques, the software was able to avoid detection by most antivirus engines, Blue Coat said. At least some software lodged inside government computers, because Blue Coat detected it "beaconing," or sending signals to the hackers that it was in place.
An Israei defense ministry spokeswoman referred questions to the military. Military officials said they were "not aware of hacking on IDF operational networks."
Blue Coat provided Reuters with an advance look at its findings and intends to publish a paper later. The security firm, based in Sunnyvale, California, is set to be acquired by private equity firm Bain Capital LLC.
Citing confidentiality agreements with clients, Blue Coat declined to say exactly where the campaign worked, and Grange said he did not know if any vital data had been stolen.
Blue Coat surmised that the attackers spoke Arabic because some of the data recovered in the investigation showed that was the default language setting in one of the programming tools.
"Not all targeted attackers need advanced tools," Blue Coat wrote in a draft paper. "As regional conflicts continue, cyber threats from groups of various skill levels will also accompany the conventional armed conflicts."
Last month, Israeli security firm Check Point Software Technologies said it had found spying programs in 10 countries that probably originated with a governmental or political group in Lebanon that deployed them over three years.
In February, Kaspersky Lab researchers said they found what they considered the first "advanced" Arabic-speaking hacking group, which they dubbed Desert Falcons. Kaspersky said the group operated from Palestine, Egypt and Turkey and claimed about 3,000 victims in 50 countries, especially targeting military, government, media, and activist computers.
(Reporting by Joseph Menn; Additional reporting by Maayan Lubell in Jerusalem; Editing by Tiffany Wu)
? View Comments (11)
????Share this story
?
????Share this story
Recommended for You
Thousands in Germany protest against Europe-U.S. trade deal
Reuters
Massive power, rising daily.
AdChoicesSolarCitySponsored
One man's last wish, 'Don't vote for Hillary Clinton.' Will it matter?
Christian Science Monitor
Babysitter Calls 911 to Say He’s Watching Abducted Child
ABC News
Deadly suicide attack in Afghanistan (11 photos)
Yahoo News
Diplomacy out, blunt talk in as Obama gets tough on GOP
Associated Press
Dental Implants: Learn The Facts And Options
AdChoicesAsk.comSponsored
Shooting that wounded baby no longer considered road rage
Associated Press
Musical chairs: Who would Shelton want in his 'Voice' seat?
Associated Press51 mins ago
Messi nets 400th goal as Barca edge past Valencia
AFP
NHL's Jarret Stoll arrested for cocaine, MDMA possession
Reuters
Shark Tank Star Reveals Easy Mortgage Payoff Trick
AdChoicesEasy Loan SiteSponsored
Maple syrup emerges as potential hero in antibiotic resistance crisis
AFP Relax News
Texas embraces handgun 'open-carry': What took 'em so long?
Christian Science Monitor56 mins ago
Mugabe 'shocked, disgusted' by South African anti-immigrant violence
Reuters
Americans Are Changing Their Minds About Pot Legalization
Takepart.com
Find Your High School Yearbook
AdChoicesClassmates.comSponsored
US military option 'old habit that dies hard': Iran FM
AFP
Fish found in suspected tsunami debris boat quarantined
Associated Press
In Aaron Hernandez murder case, question lingers: Why?
Associated Press
Kiev lists Russian military units allegedly in Ukraine
AFP
What Is Spinal Stenosis?
AdChoicesAsk.comSponsored
Missing Woman's Husband Admits to Police Wife Is Dead
ABC News Videos
Why Apple just bought 36,000 acres of forest land
BGR News
Missouri drops charges against officer indicted in shooting of man
Reuters
Load more stories
Last ones under $ 26.00
Was able to average down nicely by slapping the ask at .009 :) Go long NRTI$
long to me means 5 yrs or more GLTY
VASCO Data Security International (NASDAQ:VDSI) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 12,794,785 shares, a growth of 42.9% from the March 13th total of 8,953,197 shares, AnalystRatingsNetwork.com reports. Currently, 45.3% of the shares of the company are sold short. Based on an average daily volume of 1,616,872 shares, the short-interest ratio is currently 7.9 days.
Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of VASCO Data Security International from a “neutral” rating to an “outperform” rating and set a $28.60 price target on the stock in a research note on Friday, February 20th. Analysts at Dougherty & Co raised their price target on shares of VASCO Data Security International from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Finally, analysts at Topeka Capital Markets raised their price target on shares of VASCO Data Security International from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th.
VASCO Data Security International (NASDAQ:VDSI) opened at 24.90 on Thursday. VASCO Data Security International has a 52 week low of $7.77 and a 52 week high of $31.84. The stock has a 50-day moving average of $23. and a 200-day moving average of $24.. The company has a market cap of $981.53 million and a P/E ratio of 29.26.
VASCO Data Security International (NASDAQ:VDSI) last issued its quarterly earnings data on Tuesday, February 17th. The company reported $0.28 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.20 by $0.08. The company had revenue of $62.40 million for the quarter, compared to the consensus estimate of $54.00 million. During the same quarter in the prior year, the company posted $0.09 earnings per share. The company’s quarterly revenue was up 44.1% on a year-over-year basis. On average, analysts predict that VASCO Data Security International will post $0.99 earnings per share for the current fiscal year.
Short % of float 43.50
Will the Eagle SQEEZE out a duce by the quartely report ?
Last ones under $ 25.00
Will the Eagle SQUEEZE a duce out by report time? :)
I feel squeeze coming shortly :) VSDI$
NRTI$. :)
ERTI....here is where international companies are going with their research.
A new marijuana-based medicine may reduce the number of seizures in children and adults with severe forms of epilepsy, according to early results from an ongoing clinical trial. The drug, called Epidiolex, has a few side effects, but the preliminary results move GW Pharmaceuticals of London a step closer to debuting the third FDA-approved medicine base
d on the marijuana plant.
The research, led by Dr. Orrin Devinsky, a neurologist at New York University's Langone Medical Center, aimed to determine whether the drug compound cannabidiol was safe for young patients. Devinsky and collaborators across the country gave a daily dose for 12 weeks to 213 patients with severe epilepsy, including subgroups of patients with specific forms of the disorder such as Dravet syndrome and Lennox-Gastaut syndrome. The median age of patients in the trial was 11 years old. About 6 percent of patients, or 12 people, stopped taking the drug due to side effects including drowsiness, diarrhea and a decrease in appetite. Devinsky reported his results through the American Academy of Neurology and will present his findings at the organization's upcoming annual conference.
"I am delighted that a clinical trial in pediatric epilepsy with cannabidiol is being conducted," said Raphael Mechoulam, a chemist at the Hebrew University of Jerusalem who discovered the existence of THC, the compound in marijuana that causes the feeling of being high. "The side effects are disturbing. Pure cannabidiol is not known to cause drowsiness or tiredness." Mechoulam said he needed clarification on whether the samples administered to patients in the safety test were purified or might have contained THC, which could cause such side effects.
Though the study was not designed to measure how effective the drug is for treating epileptic seizures in patients, the researchers said they observed a substantial reduction. On average, the number of seizures in 137 patients who underwent 12 weeks of cannabidiol treatment decreased by 54 percent. Larger placebo-controlled, double-blind trials are now needed to confirm these results. GW Pharmaceuticals launched one such trial for patients with Dravet syndrome at the end of March and expects that data to be available toward the end of the year.
"These data are certainly encouraging," Dr. Shaun Hussain, who specializes in treating children with epilepsy at University of California, Los Angeles, said. "Randomized, placebo-controlled trials are a critical next step because we don't know how much of the observed response is real, and how much might be explained by caregiver optimism and other bias in the recognition and counting of seizures. In epilepsy trials, it is not uncommon for the placebo group to exhibit response rates in the 30 to 40 percent range. Given all the cannabidiol hype, placebo rates might be much higher in these highly anticipated studies."
GW Pharmaceuticals received orphan drug designation for Epidiolex from the FDA, which grants a company seven years of patent exclusivity as opposed to the standard five-year period, and already has started giving the drug to patients who failed to respond to any other treatment for free through a compassionate use trial. The company estimates that about 93,200 children in the U.S. have severe forms of epilepsy and do not respond to current treatments.
Micheal C James CEO/CFO NRTI $
I like what I see with MJ :)
Well stated jjero. IMO the squeeze will be something:)
At least the ones who bought at .0125 on oct 5 2012 and
sold on mar 14 th for .588 my 5 k casino stock has now in turn been invested wisely :):)
if it comes out of the greys I might look at PHOT again
right? was able to average down nicely went it hit .40s.
I 'm already looking forward to 2nd and 3rd quarter 2018.
Marijuana is classified as a Schedule I drug by the Drug Enforcement Administration. This places it in the class of drugs most strictly regulated by the federal government, and means it is considered to have no medicinal value for the public.
But the federal government has quietly admitted that marijuana may in fact serve as a useful treatment for treating one of the most aggressive forms of cancer.
The change: The National Institute on Drug Abuse has revised its stance on the medicinal value of marijuana by acknowledging a major study published in November by researchers at St. George's, University of London that found that the drug can have a "dramatic effect" on brain cancer.
The revised guidelines now state:
...recent animal studies have shown that marijuana can kill certain cancer cells and reduce the size of others. Evidence from one animal study suggests that extracts from whole-plant marijuana can shrink one of the most serious types of brain tumors. Research in mice showed that these extracts, when used with radiation, increased the cancer-killing effects of the radiation.
Wai Liu, one of the co-authors of the study, explained in an op-ed for the Washington Post in November that the research is "promising" and that "cannabinoids could play a role in treating one of the most aggressive cancers in adults."
The government's acknowledgement of the study bodes well for advocates for medical marijuana. The drug's Schedule I classification has stifled scientific inquiry into the effects of marijuana (both good and bad) and has resulted in a catch-22: Marijuana is labeled Schedule I because it's assumed to have no medicinal benefits, but precisely because it is labeled Schedule I, scientists generally cannot acquire funding to determine if it has any benefits.
Progress? The revised guidelines are in sync with a slow relaxing of the federal government's hard-line stance on the issue. In February, the new U.S. surgeon general struck an open-minded and gently optimistic tone when asked about medical uses in an interview.
"We have to see what the science tells us about the efficacy of marijuana," Dr. Vivek Murthy, the surgeon general of the U.S., said in an interview on CBS This Morning. "We have some preliminary data that for certain medical conditions and symptoms, marijuana can be helpful," he continued. "We have to use that data to drive policy-making."
Earlier this year, the American Academy of Pediatrics adjusted its official position on marijuana and called for the government to drop its Schedule I status in order to facilitate research on its effects.
A bill was recently introduced in the Senate by Sens. Cory Booker (D-N.J.), Rand Paul (R-Ky.) and Kirsten Gillibrand (D.-N.Y.) that would reclassify marijuana as a Schedule II drug to allow exploration of its medical benefits. If common sense prevails, it will make it into law.
h/t Raw Story
My brother recently diagnosed with MS, moved back to Colombia S.A. so he could be prescribed SATIVEX .
Cannot be prescribed in the US.
I signed the CARERS ACT. I encourage all who read this to do the same.
Irael and the UK are years ahead of the US in research.
We must enlighten our (GREYS) politicians with grey brains, hair and skin, ??
to reschedule cannabis to schedule 2 or even better 3 as should be.
It time to stop the federal and state industry of incarcerating
The BROWNS ,YELLOWS, REDS and WHITES.
Look up the lyrics to the
(prison song by System of A Down) the song is catchy also.
I want to thank all of you on this board for the great work you do. I have been adding on the dips since Oct of 2014 ever since a good friend of mine enlightened regarding (NRTI).
Last week, India Globalization, Inc. (ICG), a New York Stock Exchange-listed company in the materials sector (i.e. iron ore, steel, and electronic components), announced plans to build a cannabis growing facility in Washington State as part of its “vertical indoor farming” strategy. Talk about diversification! And with a worldwide cannabis market estimated at between $200-$400 billion, growth potential is huge.
The facility will be approximately 20,000 ft.² and house state-of-the-art software systems for security, plant tracking, lighting, enhanced climate control, and irrigation and fertilizer delivery, be pesticide free, and be ready for production within 3 months.
This isn’t ICG’s first facility. The company built a similar indoor growing facility in Rhode Island in which it has begun growing leafy green vegetables ahead of approvals needed for legal cannabis production. ICG intends to lease or sell the facilities to licensed cannabis growers.
ICG cites the growth in the medical marijuana industry is due to the use of cannabinoids extracted from cannabis such as cannabidiol (CBD), a non-psychotropic component of the drug, that is expected to help patients with seizures and other illnesses. Cannabidiol is currently in FDA trials.
A bill currently before Congress called the Compassionate Access, Research Expansion and Respect States Act (CARERS) would give states the responsibility to set medical marijuana policy, does away with federal prosecution of marijuana growing in possession, reschedules marijuana, allows states to import CBD, provides veterans access, permits financial services and banking for marijuana dispensaries, and expands research.
( NRTI) Will lead the way.
PRESS RELEASE
iBio European Plague Vaccine Patent Emerges From Opposition Period
NEWARK, DE--(Marketwired - Mar 30, 2015) - iBio, Inc. (NYSE MKT: IBIO), today announced it received notice from the European Patent Office that the opposition period expired for a bio-defense product patent granted to iBio, and no opposition was filed.
The patent, entitled "Yersinia Pestis Antigens, Vaccine Compositions and Related Methods" (European patent EP 2178558), includes claims covering plague antigens fused to a thermostable protein such as the Company's iBioModulator ™ thermostable immunomodulator, as well as vaccine compositions and a method for producing the antigen.
"This is an important extension of our commercial platform," said Robert Erwin, iBio's president. "We expect our success with vaccine and therapeutic product candidates for use against serious infectious disease agents with weapon potential, such as plague bacillus, to be of interest to governments and companies engaged in supplying disease countermeasures."
iBio technology has been successfully applied to the creation of vaccine candidates for plague and for a plague-anthrax combination vaccine with development and testing funded by the U.S. government. The U.S. Centers for Disease Control and Prevention classify plague as a Category A disease, which means "it poses a risk to national security because it can be easily disseminated or transmitted from person to person, results in high mortality rates and has the potential for a major public health impact, might cause public panic and social disruption, and requires special action for public health preparedness."
There is no plague vaccine currently approved for use in the U.S. Although killed whole-cell plague vaccines have been reported to protect against bubonic plague in animal models, such vaccines were not effective against pneumonic plague. By contrast, data previously published in the peer-reviewed scientific journal, Vaccine, demonstrated that a recombinant plague vaccine incorporating the iBioModulator protein, and produced via the iBioLaunch™ gene expression platform in green plants, provided full protection of non-human primates against aerosolized Y. pestis (pneumonic plague).
Additional infectious disease and bio-defense applications of iBio technology include an anthrax vaccine currently in a Phase 1 human clinical trial and therapeutic antibodies targeting pathogens such as influenza virus, respiratory syncytial virus, and Ebola virus.
About iBio, Inc.
iBio is developing proprietary products for the treatment of a range of fibrotic diseases including idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. IBIO-CFB03, produced using the company's iBioLaunch™ gene expression platform, is the first product candidate from this program designated for IND development. The company also offers proprietary products and product licenses to others, based on its proprietary iBioLaunch gene expression and iBioModulator™ thermostable immunomodulator protein platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has formed a subsidiary company, iBio do Brasil Biofarmaceutical Ltda., and has been collaborating with the Oswaldo Cruz Foundation (Fiocruz) since 2011 to develop a recombinant yellow fever vaccine based on iBio technology.
The iBioLaunch gene expression platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch gene expression platform and is designed to significantly improve vaccine products with both higher potency and greater duration of effect. Further information is available at: www.ibioinc.com .
FORWARD-LOOKING STATEMENTS
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
Contact Information
Investor Relations Contact
IR@IBIOINC.COM
Forward this email
This email was sent to by ir@ibioinc.com |
Update Profile/Email Address | Rapid removal with SafeUnsubscribe™ | Privacy Policy.
iBio, Inc. | 9 Innovation Way | Suite 100 | Newark | DE | 19711